GA

Gary Anderson

GS G.D. Searle: 8 patents #147 of 659Top 25%
PH Pharmacia: 1 patents #257 of 528Top 50%
📍 Maryland Heights, MO: #32 of 213 inventorsTop 20%
🗺 Missouri: #2,066 of 23,789 inventorsTop 9%
Overall (All Time): #522,905 of 4,157,543Top 15%
10
Patents All Time

Issued Patents All Time

Showing 1–10 of 10 patents

Patent #TitleCo-InventorsDate
7141599 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin Susan Gregory, Peter Isakson 2006-11-28
7132441 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor Susan Gregory, Peter C. Isakson 2006-11-07
6617345 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin Susan Gregory, Peter C. Isakson 2003-09-09
6407140 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor Susan Gregory, Peter C. Isakson 2002-06-18
6376528 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor Susan Gregory, Peter C. Isakson 2002-04-23
6342510 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist Peter C. Isakson, Susan Gregory 2002-01-29
6172096 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist Susan Gregory, Peter C. Isakson 2001-01-09
6136839 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor Peter C. Isakson, Susan Gregory 2000-10-24
5990148 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A.sub.4 hydrolase inhibitor Peter C. Isakson, Susan Gregory 1999-11-23
5700816 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A.sub.4 hydrolase inhibitor Peter C. Isakson, Susan Gregory 1997-12-23